Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26456221 | 0.89 | TAAR1 (0.46) | TSHRALDH1A1MAPTGAA | |
| SCHEMBL5219876 | 0.88 | TSHR (0.41) | TSHRALDH1A1PABPC1CA12CA2 | |
| SCHEMBL12569376 | 0.88 | TAAR1 (0.45) | TSHRALDH1A1PABPC1CYP2D6MPO | |
| SCHEMBL7533909 | 0.88 | ADRA2B (0.41) | TSHRALDH1A1PABPC1MAPTGAA | |
| SCHEMBL12571394 | 0.88 | TAAR1 (0.45) | TSHRALDH1A1PABPC1CYP2D6MPO | |
| SCHEMBL8763037 | 0.86 | TSHR (0.46) | TSHRALDH1A1PABPC1ADH1BADH1C | |
| SCHEMBL14390806 | 0.85 | CYP3A4 (0.44) | TSHRALDH1A1CYP2D6 | |
| SCHEMBL27623678 | 0.85 | TSHR (0.39) | TSHRALDH1A1PABPC1HIF1A | |
| SCHEMBL33525287 | 0.84 | ALDH1A1 (0.46) | TSHRALDH1A1MAPTNPSR1GAA | |
| SCHEMBL11286222 | 0.84 | TSHR (0.44) | TSHRALDH1A1PABPC1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-11492361-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-08 | — | — | US | disclosed |
| US-20220119417-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3886987-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-10-06 | — | — | EP | disclosed |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-14 | — | — | US | disclosed |
| US-10870663-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| WO-2020110056-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119417-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TSHR 4870/4885ALDH1A1 424/4885PABPC1 2875/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TSHR 4870/4885ALDH1A1 424/4885PABPC1 2875/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | TSHR 4870/4885ALDH1A1 424/4885PABPC1 2875/4885 |
| US-10870663-B2 | Compounds useful in HIV therapy | CCR5, SLC11A2, CD4 | TSHR 4875/4885ALDH1A1 962/4885PABPC1 4249/4885 |
| US-11492361-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | TSHR 4878/4885ALDH1A1 474/4885PABPC1 3064/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | TSHR 4875/4885ALDH1A1 962/4885PABPC1 4249/4885 |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TSHR 4878/4885ALDH1A1 474/4885PABPC1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.